|
1
|
Hu J, Chen FY, Zhou KQ, Zhou C, Cao Y, Sun
HC, Fan J, Zhou J and Wang Z: Intrahepatic cholangiocarcinoma
patients without indications of lymph node metastasis not benefit
from lymph node dissection. Oncotarget. 8:113817–113827. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahn DH and Bekaii-Saab T: Biliary cancer:
Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma
vs. gallbladder cancers: Classification and therapeutic
implications. J Gastrointest Oncol. 8:293–301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bagante F, Spolverato G, Weiss M,
Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C,
Bauer TW, Shen F, et al: Impact of morphological status on
long-term outcome among patients undergoing liver surgery for
intrahepatic cholangiocarcinoma. Ann Surg Oncol. 24:2491–2501.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bhalla A, Mann SA, Chen S, Cummings OW and
Lin J: Histopathological evidence of neoplastic progression of von
meyenburg complex to intrahepatic cholangiocarcinoma. Hum Pathol.
67:217–224. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang ME, Lei HJ, Chen MH, Yeh YC, Li CP,
Hung YP, Hsia CY, Liu CA, Chau GY and Chao Y: Evaluation of
prognostic factors and implication of lymph node dissection in
intrahepatic cholangiocarcinoma: 10-year experience at a tertiary
referral center. J Chin Med Assoc. 80:140–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Y, Liu D, Liu P, Chen Y, Yu H and
Zhang Q: Identification of biomarkers of intrahepatic
cholangiocarcinoma via integrated analysis of mRNA and miRNA
microarray data. Mol Med Rep. 15:1051–1056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang RX, Zheng Z, Li K, Wu XH and Zhu L:
Both plasma and tumor tissue miR-146a high expression correlates
with prolonged overall survival of surgical patients with
intrahepatic cholangiocarcinoma. Medicine (Baltimore).
96:e82672017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang S, Xiao J, Chai Y, Du YY, Liu Z,
Huang K, Zhou X and Zhou W: LncRNA-CCAT1 promotes migration,
invasion, and EMT in intrahepatic cholangiocarcinoma through
suppressing miR-152. Dig Dis Sci. 62:3050–3058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zu C, Liu S, Cao W, Liu Z, Qiang H, Li Y,
Cheng C, Ji L and Li J and Li J: MiR-590-3p suppresses
epithelial-mesenchymal transition in intrahepatic
cholangiocarcinoma by inhibiting SIP1 expression. Oncotarget.
8:34698–34708. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Liu Z, Fang X and Yang H:
MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in
non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Islam F, Gopalan V, Vider J, Lu CT and Lam
AK: MiR-142-5p act as an oncogenic microRNA in colorectal cancer:
Clinicopathological and functional insights. Exp Mol Pathol.
104:98–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui
J, Liu Y, Gao Z, Li J, Shen L and Lu Y: Combination of hsa-miR-375
and hsa-miR-142-5p as a predictor for recurrence risk in gastric
cancer patients following surgical resection. Ann Oncol.
22:2257–2266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wittekind C: Pitfalls in the
classification of liver tumors. Pathologe. 27:289–293. 2006.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edge SB and Compton CC: The american joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartella I and Dufour JF: Clinical
diagnosis and staging of intrahepatic cholangiocarcinoma. J
Gastrointestin Liver Dis. 24:481–489. 2015.PubMed/NCBI
|
|
17
|
Rahnemai-Azar AA, Weisbrod A, Dillhoff M,
Schmidt C and Pawlik TM: Intrahepatic cholangiocarcinoma: Molecular
markers for diagnosis and prognosis. Surg Oncol. 26:125–137. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pawlik TM: Intrahepatic
cholangiocarcinoma: From diagnosis to treatment. Hepatobiliary Surg
Nutr. 6:12017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Yin J, Li T, Yuan L, Wang D, He J,
Du X and Lu J: Upregulated circulating miR-150 is associated with
the risk of intrahepatic cholangiocarcinoma. Oncol Rep. 33:819–825.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Correa-Gallego C, Maddalo D, Doussot A,
Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel
D, Klimstra D, et al: Circulating plasma levels of MicroRNA-21 and
MicroRNA-221 are potential diagnostic markers for primary
intrahepatic cholangiocarcinoma. PLoS One. 11:e01636992016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng Q, Feng F, Zhu L, Zheng Y, Luo X,
Liu C, Yi B and Jiang X: Circulating miR-106a is a novel prognostic
and lymph node metastasis indicator for cholangiocarcinoma. Sci
Rep. 5:161032015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan R, Wang G, Xu Z, Zhao H, Chen H, Han
Y, Wang B, Zhou J, Hu H, Guo Z, et al: Up-regulated circulating
miR-106a by DNA methylation promised a potential diagnostic and
prognostic marker for gastric cancer. Anticancer Agents Med Chem.
16:1093–1100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou GY, Pan CW, Jin LX, Zheng JJ and Yi
YX: Neoalbaconol inhibits cell growth of human cholangiocarcinoma
cells by up-regulating PTEN. Am J Transl Res. 8:496–505.
2016.PubMed/NCBI
|
|
24
|
Horie Y, Suzuki A, Kataoka E, Sasaki T,
Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, et
al: Hepatocyte-specific pten deficiency results in steatohepatitis
and hepatocellular carcinomas. J Clin Invest. 113:1774–1783. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trimboli AJ, Cantemir-Stone CZ, Li F,
Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H,
Chong JL, et al: Pten in stromal fibroblasts suppresses mammary
epithelial tumours. Nature. 461:1084–1091. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu X, Kobayashi S, Qiao W, Li C, Xiao C,
Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, et al: Induction
of intrahepatic cholangiocellular carcinoma by liver-specific
disruption of Smad4 and pten in mice. J Clin Invest. 116:1843–1852.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marsh V, Davies EJ, Williams GT and Clarke
AR: PTEN loss and KRAS activation cooperate in murine biliary tract
malignancies. J Pathol. 230:165–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chung JY, Hong SM, Choi BY, Cho H, Yu E
and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and
PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res.
15:660–667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YR, Chen M and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor: New modes
and prospects. Nat Rev Mol Cell Biol. 19:547–562. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rimawi MF, De Angelis C, Contreras A,
Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero
A, et al: Low PTEN levels and PIK3CA mutations predict resistance
to neoadjuvant lapatinib and trastuzumab without chemotherapy in
patients with HER2 over-expressing breast cancer. Breast Cancer Res
Treat. 167:731–740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malaney P, Palumbo E, Semidey-Hurtado J,
Hardee J, Stanford K, Kathiriya JJ, Patel D, Tian Z, Allen-Gipson D
and Davé V: PTEN Physically interacts with and regulates
E2F1-mediated transcription in lung cancer. Cell Cycle. 17:947–962.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang
D, Wang Y, Roberts TM, Liu P, Zhao JJ and Cheng H: PTEN deficiency
sensitizes endometrioid endometrial cancer to compound PARP-PI3K
inhibition but not PARP inhibition as monotherapy. Oncogene.
37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ikenoue T, Terakado Y, Nakagawa H, Hikiba
Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, et
al: Corrigendum: A novel mouse model of intrahepatic
cholangiocarcinoma induced by liver-specific Kras activation and
Pten deletion. Sci Rep. 7:395672017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikenoue T, Terakado Y, Nakagawa H, Hikiba
Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, et
al: A novel mouse model of intrahepatic cholangiocarcinoma induced
by liver-specific Kras activation and Pten deletion. Sci Rep.
6:238992016. View Article : Google Scholar : PubMed/NCBI
|
